Degree of hydrolysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Whey protein hydrolysate appears in infant formula, sports nutrition, and clinical nutrition. In infant formula, extensively hydrolyzed products are used when a reduced allergenicity is desired, though not all hydrolysates are hypoallergenic. In sports products, the ingredient is marketed for rapid amino acid delivery, but the practical advantage over intact whey protein remains debated. Research often compares hydrolysate with isolate or concentrate for absorption kinetics, muscle protein synthesis, and gastrointestinal tolerance. Regulatory categories differ by country, and label terms such as partially hydrolyzed or extensively hydrolyzed are defined in some jurisdictions but not others.
Whey protein hydrolysate is a dairy ingredient made by treating whey protein with proteolytic enzymes. The starting material is whey, the liquid remaining after cheese or casein production, and its main proteins include beta-lactoglobulin, alpha-lactalbumin, and bovine serum albumin. Enzyme action breaks peptide bonds, producing shorter peptides and some free amino acids. The result is not a single uniform substance; composition depends on whey source, enzyme type, hydrolysis conditions, and downstream filtration. Hydrolysates are often described by average peptide length or degree of hydrolysis rather than by one fixed molecular weight.
Compared with whey protein concentrate or isolate, hydrolysate has a smaller average peptide size and a higher proportion of low-molecular-weight fractions. This change can affect solubility, viscosity, osmolality, taste, and foam formation. Some hydrolysates are bitter because hydrophobic peptides are exposed during cleavage. The term hydrolysate does not indicate a guaranteed peptide profile; two products with the same reported hydrolysis value can differ in peptide sequence and residual intact protein. Commercial specifications usually state protein content, moisture, ash, fat, and microbiology, while peptide distribution may be reported as a range.
Molecular weight distribution is a central compositional feature, and hydrolysis shifts the population toward lower-mass peptides, often below ten kilodaltons in extensively treated products. Enzyme choice, reaction time, temperature, pH, and enzyme-to-substrate ratio influence the peptide profile. Ultrafiltration or diafiltration may remove enzymes, salts, and smaller molecules. Because peptide size affects solubility, taste, foaming, and digestibility, manufacturers specify molecular weight ranges. However, two hydrolysates with similar average molecular weight can differ in peptide sequence and functional behavior.
Bitterness often increases with hydrolysis because hydrophobic peptides are exposed. Processing strategies therefore include selecting enzymes that cleave at specific sites, using exopeptidases to remove terminal hydrophobic residues, or blending hydrolysates with other ingredients. Allergenicity is another consideration: extensive hydrolysis can reduce IgE-binding epitopes, but it does not guarantee absence of allergenic potential. Regulatory frameworks vary in how they classify hydrolyzed whey for infant formula or sports products. Claims about reduced allergenicity or faster absorption depend on the specific product and study design, and are not uniform across all hydrolysates.
Whey protein hydrolysate is made by cleaving peptide bonds in whey proteins. The starting material is usually whey protein concentrate or isolate obtained during cheese or casein production. Proteolytic enzymes, acid, or heat can drive hydrolysis, although commercial processes favor controlled enzymatic treatment. The degree of hydrolysis describes the proportion of peptide bonds broken and separates partial from extensive hydrolysates. The resulting powder contains short peptides, free amino acids, residual intact protein, minerals, lactose, and fat in proportions that depend on the starting whey and downstream filtration.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to light tan powder | Color can vary with hydrolysis and drying |
| Protein content | 70–90% dry basis | Lower if ash, lactose, or moisture remain |
| Degree of hydrolysis | Typically 5–35% | Partially and extensively hydrolyzed types differ |
| Solubility | Water-soluble | High across common food pH ranges, though peptide dependent |
| Common synonyms | Whey hydrolysate; hydrolyzed whey protein | Sometimes abbreviated WPH on labels |
Dried hydrolysate powders are usually off-white to pale yellow and are marketed as free-flowing powders or liquid concentrates. They are used in foods, beverages, and specialized nutrition products where rapid dispersion or reduced allergenicity is desired, although residual allergenic epitopes can remain depending on hydrolysis extent. The term hydrolysate does not imply a single molecular weight cutoff or a guaranteed clinical effect. Labels may state degree of hydrolysis, protein content, or peptide length profile, but analytical definitions vary across suppliers and jurisdictions.
Whey protein hydrolysate is a dairy ingredient produced by treating whey protein concentrate or isolate with proteolytic enzymes, acids, or heat under controlled conditions. The process cleaves peptide bonds and reduces average peptide size compared with intact whey proteins. Products are often described by degree of hydrolysis, which estimates the percentage of peptide bonds broken. Hydrolysates occupy a distinct category from concentrates and isolates because their peptide profile, solubility, and taste differ, even when the parent protein source is similar. Commercial production typically begins with pasteurized whey, followed by filtration, enzymatic treatment, inactivation, and drying.
Hydrolysates usually contain 70% to 90% protein on a dry basis, with variable ash, fat, and carbohydrate. Solubility in water is generally high over a broad pH range, though bitter notes can appear from exposed hydrophobic peptides. The powder tends to absorb moisture and may brown during prolonged warm storage. Applications span sports nutrition, clinical nutrition, infant formulas, and flavor systems. Regulatory status and labeling rules differ by country. A key open question is whether a given peptide profile reliably predicts functional or sensory behavior across different food matrices.
Whey protein hydrolysate is a dairy ingredient made by breaking peptide bonds in whey proteins. Enzymes such as proteases, or in some processes acid or heat, cleave the protein chains into shorter peptides and free amino acids. The starting material may be sweet whey, acid whey, whey protein concentrate, or whey protein isolate. Because raw materials and reaction conditions differ, the final mixture is not a single uniform substance. Its peptide profile, mineral content, and residual lactose depend on the source and the processing steps used.
Regulatory treatment of whey protein hydrolysate depends on the country and intended use. In many jurisdictions it is regulated as a food ingredient or food for special dietary use, not as a drug. Labeling rules govern allergen statements, protein content claims, and ingredient names. Some markets have specific rules for infant formula ingredients, where hydrolysates may be used for particular dietary purposes. Regulations generally focus on safety, truthful labeling, and manufacturing standards rather than on therapeutic effects. Scientific questions about specific peptide activities remain an active area of research rather than a settled regulatory category.
Whey protein hydrolysate powders are hygroscopic and can absorb moisture from air. Moisture uptake may lead to caking, reduced flowability, and gradual peptide degradation. Manufacturers typically specify cool, dry storage and sealed packaging to limit these changes. Water activity, rather than water content alone, is often monitored because it better predicts microbial and chemical stability. High temperatures can accelerate Maillard reactions between peptides and residual sugars, altering color and flavor. Exact shelf lives depend on formulation, packaging, and initial moisture, so they are usually determined by product-specific stability testing.
Analytical testing for whey protein hydrolysate focuses on peptide size distribution, degree of hydrolysis, protein content, moisture, ash, and microbiological quality. Size-exclusion chromatography and mass spectrometry can characterize peptide profiles, while Kjeldahl or combustion methods estimate total nitrogen and protein. Amino acid analysis quantifies free and total amino acids. Because peptide mixtures are complex, no single method captures every property, and results can vary between laboratories. Standardized methods and reference materials help improve comparability, but full sequence-level characterization remains uncommon in routine quality control.
Enzyme choice influences the peptide size distribution and the resulting functional properties. Some proteases cut at specific amino acid residues, while others act more broadly, so two hydrolysates with the same degree of hydrolysis can differ in peptide sequences. Short peptides are generally more water-soluble and less likely to form gels under heat, although bitterness can increase when hydrophobic residues become exposed. The relationship between peptide length, taste, and bioactivity is an active area of study, and not all proposed effects are established in human trials.
Composition tables often report protein content on a dry basis, ash, moisture, fat, and lactose. Because hydrolysis adds water to peptide bonds, the total mass yield can appear slightly higher than the original protein if residual salts and water are counted. Some products are further processed by ultrafiltration, spray drying, or decolorization, which alters mineral content and flavor. Product labels may distinguish partially hydrolyzed from extensively hydrolyzed whey, but these terms are not always defined by a single numerical threshold across regions.
Whey protein hydrolysate is a dairy ingredient made by treating whey protein with proteases that cleave peptide bonds. The starting material is typically whey protein concentrate or isolate, which contains beta-lactoglobulin, alpha-lactalbumin, and smaller amounts of bovine serum albumin and immunoglobulins. Hydrolysis shortens protein chains into peptides and free amino acids, changing solubility, viscosity, and flavor compared with intact whey protein. The extent of cleavage is commonly described by degree of hydrolysis, a percentage of broken peptide bonds relative to total bonds.
== Treatment == Emergency lowering of potassium levels is needed when new arrhythmias occur at any level of potassium in the blood, or when potassium levels exceed 6.5 mmol/L. Several agents are used to temporarily lower K+ levels. The choice depends on the degree and cause of the hyperkalemia, and other aspects of the person's condition.
=== Musculoskeletal === Isotretinoin has a number of muscoloskeletal effects. Myalgia (muscular pain) and arthralgia (joint pain) are common side effects. Retinoids, such as high dose etretinate, are well known to cause bone changes, the most common type of which is hyperostotic changes (excessive bone growth), especially in growing children and adolescents. While excessive bone growth has been raised as a possible side effect of isotretinoin, a 2006 review found little evidence for this. Other problems include premature epiphyseal closure and calcification of tendons and ligaments. The bones of the spine and feet are most commonly affected. Risk factors for skeletal effects include older age, greater dosage, and longer course of treatment. Most bone changes cause no symptoms and may only be noticed using X-ray imaging.
== Treatment == The treatment to battle the disease chorea-acanthocytosis is completely symptomatic. For example, botulinum toxin injections can help to control orolingual dystonia. Deep brain stimulation is a treatment that has varied effects on the people suffering from the symptoms of this disease, for some it has helped in a large way and for other people it did not help whatsoever, it is more effective on specific symptoms of the disease. Patients with chorea-acanthocytosis should undergo a cardiac evaluation every five years to look for cardiomyopathy.
== Anticancer properties == Anticancer activities of cecropin B, cecropin P1, and Shiva-1 were first demonstrated with in vitro studies of mammalian leukemia and lymphoma cell lines, where cells were sensitive to peptide concentrations on the order of 10−6 M. Two multidrug-resistant breast and ovarian cancer cell lines also showed sensitivity to the peptides. Further, peptide anticancer activity is reported as being complete within one hour of treatment. In vivo studies of murine ascitic colon adenocarcinoma cells showed a similar trend, where mice treated with cecropin B exhibited increased survival time compared to untreated mice. Structural studies of cecropin B and its derivative cecropin B3 showed that anticancer activity arises from the ability of the antimicrobial peptides to form pores in stomach carcinoma cell membranes. Measuring electrical currents on cell surfaces showed that cecropin B, but not cecropin B3, induces outward currents indicative of pore formation. Further, cecropin B3 lacks an amphipathic group present in cecropin B, suggesting that this amphipathic group is necessary for cecropin B to insert into cell membranes and form pores. Cecropin B has strong activity on bacteria as well as cancer cells, while B3 has little effect on either. Notably, another derivative, cecropin B1, has two amphipathic regions and exhibits potent activity against human leukemia cell lines at concentrations that do not affect normal fibroblasts or red blood cells.
Sources: en.wikipedia.org
As Western imports became popular, demand for Japanese art declined within Japan itself. In Europe and America, the new availability of Japanese art led to a fascination for Japanese culture; a craze known in Europe as Japonisme. Imperial patronage, government sponsorship, promotion to new audiences, and Western technology combined to foster an era of Japanese artistic innovation. In the decorative arts, Japanese artists reached new levels of technical sophistication. Today, Masayuki Murata owns more than 10,000 Meiji art works and is one of the most enthusiastic collectors. From that time, most of the excellent works of Meiji Art were bought by foreign collectors and only a few of them remained in Japan, but because he bought back many works from foreign countries and opened the Kiyomizu Sannenzaka Museum, the study and reevaluation of Meiji Art rapidly advanced in Japan from the 21st century. Nasser Khalili is also one of the world's most dedicated collectors of Meiji art, and his collection encompasses many categories of Meiji art. The Japanese Imperial Family also owns excellent works of Meiji Art, some of which were donated to the state and are now stored in the Museum of the Imperial Collections.
=== Metabolic complications === Metabolic complications include the refeeding syndrome characterised by hypokalemia, hypophosphatemia and hypomagnesemia. Hyperglycemia is common at the start of therapy, but can be treated with insulin added to the TPN solution. Hypoglycaemia is likely to occur with abrupt cessation of TPN. Liver dysfunction can be limited to a reversible cholestatic jaundice and to fatty infiltration (demonstrated by elevated transaminases). Severe hepatic dysfunction is a rare complication. Overall, patients receiving TPN have a higher rate of infectious complications. This can be related to hyperglycemia.
== X == Xiaoliang Sunney Xie (born 1962), Chinese-American biochemist, pioneer in the field of Single Molecule Microscopy and CARS (Coherent Anti-Stokes Raman Spectroscopy) microscopy Xie Yi (born 1967), Chinese chemist, member of the Chinese Academy of Sciences and a fellow of the Royal Society of Chemistry.
== Career == In 1953 he was elected to a Life Fellowship at King's, where he remained for the whole of his academic career, holding the positions of Financial Tutor (1956–1959), Director of Studies in Natural Sciences (1961–1981), Vice Provost (1981–1986) and Praelector (1989–1992), as well as co-editor of the College Register. In 1954 he was appointed as University Demonstrator in biochemistry, and in 1959 was promoted to University Lecturer. From 1964 to 1965, he worked at the Engelhardt Institute of Molecular Biology in Moscow as part of a UK-USSR exchange program. Dixon was an editor of The Biochemical Journal, and was Deputy Chairman of the Editorial Board from 1977 to 1982. He was secretary of the Nomenclature Committee of the International Union of Biochemistry from 1977 to 1982 and chairman from 1983 to 1988, and after his retirement remained an advisory member. Dixon's research in chemistry and biochemistry led to 136 published papers. His interests included the pH-dependence of enzyme-catalysed reactions, arsenic biochemistry, protein modification and other aspects of enzymology. His particular interest in applications of methods from organic chemistry to biochemistry led to a proposed treatment for Wilson's disease. In 1957 he married Heather Spittle with whom he had three children. After his death, a set of rooms in the Gibbs' Building in King's College was named the Hal Dixon Rooms in his memory.
3-Phosphoglyceric acid (3PG, 3-PGA, or PGA) is the conjugate acid of 3-phosphoglycerate or glycerate 3-phosphate (GP or G3P). This glycerate is a biochemically significant metabolic intermediate in both glycolysis and the Calvin-Benson cycle. The anion is often termed as PGA when referring to the Calvin-Benson cycle. In the Calvin-Benson cycle, 3-phosphoglycerate is typically the product of the spontaneous scission of an unstable 6-carbon intermediate formed upon CO2 fixation. Thus, two equivalents of 3-phosphoglycerate are produced for each molecule of CO2 that is fixed. In glycolysis, 3-phosphoglycerate is an intermediate following the dephosphorylation (reduction) of 1,3-bisphosphoglycerate.
Sources: en.wikipedia.org
==== United Kingdom ==== In the United Kingdom, Lyme disease is the primary human tick-borne disease of concern, with a 1-year Lyme disease incidence of 12/100,000 reported in 2019. The number of laboratory-confirmed cases of Lyme disease has been rising steadily since voluntary reporting was introduced in 1986 when 68 cases were recorded in the UK and Ireland combined. In the UK there were 23 confirmed cases in 1988 and 19 in 1990, but 973 in 2009 and 953 in 2010. Provisional figures for the first 3 quarters of 2011 show a 26% increase on the same period in 2010. It is thought, however, that the actual number of cases is significantly higher than suggested by the above figures, with England's Health Protection Agency estimating that there are between 2,000 and 3,000 cases in England and Wales per year (with an average of around 15% of the infections acquired overseas), while Dr Darrel Ho-Yen, Director of the Scottish Toxoplasma Reference Laboratory and National Lyme Disease Testing Service, believes that the number of confirmed cases should be multiplied by 10 "to take account of wrongly diagnosed cases, tests giving false results, sufferers who weren't tested, people who are infected but not showing symptoms, failures to notify and infected individuals who don't consult a doctor." Lyme disease is a notifiable disease in Scotland. Mandatory reporting, limited to laboratory test results only, is required in the UK under the provisions of the Health Protection (Notification) Regulations 2010.
== References == This article was submitted to WikiJournal of Science for external academic peer review in 2017 (reviewer reports). The updated content was reintegrated into the Wikipedia page under a CC-BY-SA-3.0 license (2018). The version of record as reviewed is: Mike Christie; et al. (2018). "Radiocarbon dating" (PDF). WikiJournal of Science. 1 (1): 6. doi:10.15347/wjs/2018.006. Wikidata Q55120317.
Biopharmaceuticals may be produced from microbial cells (e.g., recombinant E. coli or yeast cultures), mammalian cell lines (see Cell culture) and plant cell cultures (see Plant tissue culture) and moss plants in bioreactors of various configurations, including photo-bioreactors. Important issues of concern are cost of production (low-volume, high-purity products are desirable) and microbial contamination (by bacteria, viruses, mycoplasma). Alternative platforms of production which are being tested include whole plants (plant-made pharmaceuticals).
A paradox of German policy was that the collaborators such as Hácha were held in contempt by the Nazis as "riff raff" while those who clung most defiantly to their sense of Czech identity were considered to be the better subjects of Germanizaton. Heydrich in a report to Berlin stated that Hácha was "incapable of Germanization" as "he is always sick, arrives with a trembling voice and attempts to evoke pity that demands our mercy". By contrast, Heydrich had a grudging respect for Elias, noting that he was youthful, healthy, and a determined defender of Czech interests, which led Heydrich to conclude that he must have some German blood. Aside from the inconsistency of animosity towards Slavs, there is also the fact that the forceful but restrained policy in Czechoslovakia was partly driven by the need to keep the population nourished and complacent so that it can carry out the vital work of arms production in the factories. By 1939, the country was already serving as a major hub of military production for Germany, manufacturing aircraft, tanks, artillery, and other armaments.
== Synthesis == Hexobarbital can be synthesized by reacting cyclohex-1-enyl 2-cyanopropanoate with guanidine and sodium methylate. A hexobarbital sodium intermediate is then formed which can be methylated with dimethyl sulfate. Another pathway for hexobarbital synthesis is reacting ethyl 2-cyano-2-(cyclohex-1-enyl)propanoate with N-methylurea. This reaction is done in two stages, in the first stage the reactants are added with tert-butylate in tert-butyl alcohol at 20-50 °C. In the second stage hydrogen chloride is added with ethanol and water as solvent.
Sources: en.wikipedia.org
It is made from whey, the liquid byproduct of cheese or casein manufacture. The whey protein is treated with enzymes that cleave peptide bonds. The resulting mixture contains peptides of varying lengths plus some free amino acids.
Whey protein isolate is largely intact protein with a high protein content by dry weight. Hydrolysate has been enzymatically broken into smaller peptides, which can change taste, osmolality, and absorption behavior. Both can have similar total amino acid content, but their peptide profiles differ.
No. Hypoallergenic status depends on the extent of hydrolysis and the residual allergenic protein fragments. Regulatory bodies set specific criteria for products labeled hypoallergenic or extensively hydrolyzed. A hydrolysate not meeting those criteria may still contain allergenic epitopes.
Both derive from whey, but hydrolysate has been treated to break peptide bonds, producing shorter peptides. Isolate is filtered to high protein content with much of its original protein structure intact. The two differ in peptide size, taste, and functional properties.